Publicacións nas que colabora con Javier Sastre Valera (13)

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

2020

  1. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: The randomised phase III VISNÚ-1 trial

    ESMO Open, Vol. 5, Núm. 6

2019

  1. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2

    Journal of Clinical Oncology

2018

  1. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

  2. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

    Oncologist, Vol. 23, Núm. 11, pp. 1271-e128

2015

  1. Clinical guideline SEOM: hepatocellular carcinoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 988-995

  2. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours

    European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380

  3. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

    Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324

2014

  1. Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base

    Clinical and Translational Oncology, Vol. 16, Núm. 11, pp. 959-965

2012

  1. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2011

  1. Evaluación ecónomica de capecitabina + cisplatino frente a 5-FU + cisplatino en el tratamiento en primera línea de cáncer gástrico avanzado en España

    Pharmacoeconomics - Spanish Research Articles, Vol. 8, Núm. 2, pp. 51-58

  2. Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain

    Clinical and Translational Oncology, Vol. 13, Núm. 12, pp. 862-868

2009

  1. Cáncer colorrectal

    You and Us